

CLAIM AMENDMENT

The following claim listing replaces all previous versions of the claims.

Claims 1 to 20. Canceled.

21. (Currently amended) A uPA active site-targeting peptide compound that binds to the endosite and one or more exosites of (i) tcuPA or (ii) a fragment or subunit of tcuPA, which fragment or subunit retains the uPA (1) enzymatic endosite and (2) a uPAR-binding epitope, such that said peptide compound covalently modifies the endosite; said peptide compound including being a member of the group consisting of:

~~(a) a detectable label;~~

~~(b) a therapeutic moiety, or~~

~~(c) a chelator that is optionally bound to a detectable label or a therapeutic moiety;~~

(a) (Chelator)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA;

(b) (Label-Chelator)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA;

(c) (Label)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA; and

(d) (Therapeutic moiety)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA,

wherein Label is a detectable label, each Xaa is independently an amino acid; and
wherein the peptide compound localizes said chelator, detectable label or therapeutic moiety to the uPA active site.

22-24 (Canceled)

25. (Currently amended) A method for detecting the presence of uPAR (i) on the surface of a cell, (ii) in a tissue, (iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing uPAR due to a pathological state, comprising the steps of:

(a) contacting the cell, tissue, organ or sample with the molecule or composition of ~~any one of claims 13, 16, 21 or 22~~ claim 21; and

(b) detecting the presence of the label associated with the cell, tissue, organ or sample.

26. Canceled.

27. (Original) The method of claim 25 wherein the contacting and the detecting are *in vitro*.

28. Canceled.

29. (Original) The method of claim 25 wherein the contacting is *in vivo* and the detecting is *in vitro*.

30. Canceled.

31. (Original) The method of claim 25, wherein the contacting and the detecting are *in vivo*.

32 to 34. Canceled.

35. (Currently amended) A diagnostic or therapeutic uPA active site-targeting peptide pharmaceutical composition comprising:

(a) an effective amount of the peptide of claim 21 ~~to which is bound directly or indirectly a detectable label or therapeutically active moiety~~; and

(b) a pharmaceutically acceptable carrier.

36. Canceled.
37. Canceled.
38. (Original) The pharmaceutical composition of claim 35 in a form suitable for injection.
39. Canceled.
40. Canceled.
41. (Original) The therapeutic pharmaceutical composition of claim 35 wherein the therapeutically active moiety is a radionuclide.
42. Canceled.
43. (Original) The therapeutic pharmaceutical composition of claim 41, wherein the radionuclide is selected from the group consisting of ^{47}Sc , ^{67}Cu , ^{90}Y , ^{109}Pd , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{199}Au , ^{211}At , ^{212}Pb and ^{217}Bi .
44. Canceled.
45. (Original) A method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an effective amount of a therapeutic pharmaceutical composition according to claim 35.
46. Canceled.

47. (Original) A method for inhibiting the invasiveness of tumor cells comprising contacting the cells with an effective amount of a therapeutic pharmaceutical composition according to claim 35.

48. Canceled.

49. (Original) A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to the subject an effective amount of a pharmaceutical composition according to claim 35.

50. (New) The compound of claim 21, which is:

(Chelator)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA,

wherein each Xaa is independently an amino acid.

51. (New) The compound of claim 21, which is:

(Label-Chelator)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA,

wherein Label is a detectable label and each Xaa is independently an amino acid.

52. (New) The compound of claim 21, which is:

(Label)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA,

wherein Label is a detectable label and each Xaa is an amino acid.

53. (New) The compound of claim 21, which is:

(Therapeutic moiety)-(Xaa)₂₋₆-(Lys,Arg)-(alkylating group)-uPA,

wherein each Xaa is independently an amino acid.

54. (New) A diagnostic or therapeutic uPA active site-targeting pharmaceutical composition, comprising an effective amount of the peptide of claim 50 and a pharmaceutically acceptable carrier.

55. (New) A diagnostic or therapeutic uPA active site-targeting pharmaceutical composition, comprising an effective amount of the peptide of claim 51 and a pharmaceutically acceptable carrier.

56. (New) A diagnostic or therapeutic uPA active site-targeting pharmaceutical composition, comprising an effective amount of the peptide of claim 52 and a pharmaceutically acceptable carrier.

57. (New) A diagnostic or therapeutic uPA active site-targeting pharmaceutical composition, comprising an effective amount of the peptide of claim 53 and a pharmaceutically acceptable carrier.